Aprea Therapeutics Advances WEE1 Inhibitor APR-1051 in Phase 1 Trial for Hard-to-Treat Cancers
Aprea Therapeutics Inc. has provided updates on its clinical trials for APR-1051 and ATRN-119. In the Phase 1 trial of APR-1051, a WEE1 kinase inhibitor, 3 out of 4 patients at the 100 mg dose achieved stable disease in difficult-to-treat cancers. The trial has progressed to a 150 mg dose. For ATRN-119, the recommended Phase 2 dose is 1,100 mg. Results were presented at the AACR-NCI-EORTC conference on October 24, 2025. Future studies may explore APR-1051 in combination with checkpoint inhibitors.
Aprea Therapeutics Inc. has announced updates on its ongoing clinical trials for two investigational cancer therapies, APR-1051 and ATRN-119. In the Phase 1 ACESOT-1051 dose-escalation trial of APR-1051, a WEE1 kinase inhibitor, 3 out of 4 patients at the 100 mg once daily dose level achieved stable disease in heavily pretreated gastrointestinal and gynecologic malignancies. Dose escalation has continued to the 150 mg once daily cohort. For ATRN-119, an ATR kinase inhibitor, the recommended Phase 2 dose (RP2D) has been identified as 1,100 mg once daily in the ABOYA-119 dose-escalation study. Results from these studies were presented in posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics on October 24, 2025. Future studies may evaluate APR-1051 in combination with checkpoint inhibitors. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aprea Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9572964-en) on November 12, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
